1736-21-6

Basic information

• Product Name: 3-(4-FLUOROPHENYL)-5-METHYL-4-ISOXAZOLECARBOXYLIC ACID
• Synonyms: BUTTPARK 99\12-50;3-(4-FLUOROPHENYL)-5-METHYLISOXAZOLE-4-CARBOXYLIC ACID;3-(4-FLUOROPHENYL)-5-METHYL-4-ISOXAZOLECARBOXYLIC ACID;4-Isoxazolecarboxylic acid, 3-(4-fluorophenyl)-5-Methyl-;3-(4-Fluorophenyl)-5-methylisoxazol-4-carboxylic Acid;3-(4-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxylic acid
• CAS NO: 1736-21-6
• Molecular Formula: C₁₁H₈FNO₃
• Molecular Weight: 221.18
• Product Categories: Building Blocks;Heterocyclic Building Blocks;Isoxazoles;Building Blocks;Chemical Synthesis;Fluorinated Building Blocks;Heterocyclic Building Blocks;Heterocyclic Fluorinated Building Blocks;Other Fluorinated Heterocycles
• Mol File: 1736-21-6.mol
• Article Data: 7

Chemical Properties

• Melting Point: 198-202 °C
• Boiling Point: 361.6 °C at 760 mmHg
• Flash Point: 172.5 °C
• Appearance: /
• Density: 1.35g/cm³
• Vapor Pressure: 7.36E-06mmHg at 25°C
• Refractive Index: 1.56
• Storage Temp.: 2-8°C
• Solubility: soluble in Methanol
• Sensitive: Moisture & Light Sensitive
• CAS DataBase Reference: 3-(4-FLUOROPHENYL)-5-METHYL-4-ISOXAZOLECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-FLUOROPHENYL)-5-METHYL-4-ISOXAZOLECARBOXYLIC ACID(1736-21-6)
• EPA Substance Registry System: 3-(4-FLUOROPHENYL)-5-METHYL-4-ISOXAZOLECARBOXYLIC ACID(1736-21-6)

Safety Data

• Hazard Codes: Xi:Irritant
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 1736-21-6(Hazardous Substances Data)

Usage

General Description

3-(4-Fluorophenyl)-5-methyl-4-isoxazolecarboxylic acid is a chemical compound with the molecular formula C11H8FNO3. It is a derivative of isoxazolecarboxylic acid, and it contains a fluorophenyl and methyl group attached to the isoxazole ring. 3-(4-FLUOROPHENYL)-5-METHYL-4-ISOXAZOLECARBOXYLIC ACID is used in the pharmaceutical industry as a building block for the synthesis of various drugs and pharmaceutical compounds. It has also shown potential for activity against certain biological targets, such as enzymes or receptors, making it valuable for medicinal chemistry research. Additionally, it has been investigated for its potential anti-inflammatory and analgesic properties, making it a compound of interest for the development of new therapeutic agents.

InChI:InChI=1/C11H8FNO3/c1-6-9(11(14)15)10(13-16-6)7-2-4-8(12)5-3-7/h2-5H,1H3,(H,14,15)

Upstream product

• 159693-09-1 3-(4-Fluoro-phenyl)-5-methyl-isoxazole-4-carboxylic acid methyl ester 
• 393165-20-3 (Z)-N-hydroxy-4-fluoro-benzenecarboximidoyl chloride 
• 954230-39-8 3-(4-fluoro-phenyl)-5-methyl-isoxazole-4-carboxylic acid ethyl ester 
• 459-57-4 4-fluorobenzaldehyde 
• 459-23-4 4-fluorobenzaldoxime 
• 42202-95-9 4-fluoro-N-hydroxybenzimidoyl chloride 
• 105-45-3 acetoacetic acid methyl ester 

Downstream Products

• 2546-21-6 3-(4-fluorophenyl)-5-methyl-N-phenylisoxazole-4-carboxamide 
• 1402042-26-5 1-[4-[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]phenyl]ethanone 
• 850831-57-1 4-[3-(4-fluorophenyl)-5-methyl-4-isoxazolyl]benzonitrile 
• 1402042-27-6 3-(4-fluorophenyl)-4-(4-methoxyphenyl)-5-methyl-1,2-oxazole 
• 491875-99-1 3-(4-fluoro-phenyl)-5-methylisoxazole 
• 1431329-33-7 6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-nicotinonitrile 
• 1159600-38-0 6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-N-(tetrahydro-pyran-4-yl)-nicotinamide 
• 1159600-41-5 (1,1-dioxo-1λ⁶-thiomorpholin-4-yl)-{6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-methanone 
• 1159600-36-8 6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-N-isopropyl-nicotinamide 
• 1159600-35-7 N-cyclopropylmethyl-6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-nicotinamide 
• 1159600-39-1 {6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-morpholin-4-yl-methanone 
• 1159600-34-6 6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-N-(2,2,2-trifluoro-ethyl)-nicotinamide 
• 1018297-63-6 [3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-yl]-methanol 
• 1159600-32-4 6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-nicotinic acid 

Relevant articles and documents

(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV

The invention relates to an administration unit comprising a compound of formula and/or pharmaceutically acceptable salts thereof, and to a packaging comprising the administration unit according to the invention.

PROCESS FOR THE PREPARATION OF ISOXAZOLYL- METHOXY NICOTINIC ACIDS

The present invention relates to a process for the preparation of a compound of formula (I) wherein R1 and R2 are as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds.

NOVEL SOLID FORMS

The instant invention relates to novel solid forms of the compound of formula (I) as well as solvates, inclusion complexes with other suitable compounds, processes for their manufacture, pharmaceutical compositions containing these solid forms, and their